



TRIDENT LIFELINE LIMITED
(Formerly Trident Lifeline Private Limited)

CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

Date: 23.12.2024

BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400001.	Stock ID: TLL Scrip Code: 543616
---	---

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting held on December 23, 2024.

Ref: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, December 23, 2024 at the registered office of the Company has considered and approved including following item:

1. The proposal to acquire 51% i.e. 39,67,800 (Thirty-Nine Lakh Sixty-Seven Thousand Eight Hundred) equity shares of Rs. 10/- each of the TRIDENT MEDIQUIP LIMITED (CIN: U33309GJ2019PLC110421).

Further, the information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith.as **Annexure – A**.

The Board Meeting commenced at 07:20 p.m. and concluded at 07:50 p.m.

You are requested to kindly take the note of above on records.

Thanking You,

Yours Faithfully
For **Trident Lifeline Limited**,

NIKITA SHARMA
COMPANY SECRETARY AND COMPLIANCE OFFICER
M. NO.: A60595

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.

Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.

Tel : +91 261 2490224, 2490225

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

Annexure-A
Information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	TRIDENT MEDIQUIP LIMITED (CIN: U33309GJ2019PLC110421) Company incorporated under the provisions of the Companies Act, 2013, having its Registered Office in Surat, Gujarat. Capital Details: Authorized Share Capital: Rs. 8,00,00,000 /- divided into 80,00,000 Equity Shares of Rs.10/- each Paid-up Share Capital: Rs. 7,78,00,000/- divided into 77,80,000 Equity Shares of Rs.10/- each Turnover: Rs. 20,58,08,887/-
2	whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Yes , TRIDENT MEDIQUIP Limited (TMQL), a public Limited Company in which Mr. Hardik Jigishkumar Desai, Amit Bhupendra Halvawala and Mr. Chetan Chandrakant Jariwala (director's Relative) are member cum Director and all of above are part of promoters/promoter group/board of acquiring Company i.e being Trident Lifeline Limited (The Company), have an interest in the entity being acquired (TMQL). The transaction is being undertaken on an arm's length basis.
3	Industry to which the entity being acquired belongs	Pharmaceuticals Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for	This acquisition would allow the company to partner with the leading and fast-growing market of medical &

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

	acquisition of target entity, if its business is outside the main line of business of the listed entity)	surgical and/or diagnostic equipments, along with pharmaceuticals and allied products.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	The acquisition is within the overall limit approved by the Shareholders of the Company under Section 186 of the Companies Act, 2013.
6	Indicative time period for completion of the acquisition	Approx. One Month
7	Consideration - whether cash consideration or share swap and details of the same;	Acquisition of shares is by way of Cash
8	Cost of acquisition or the price at which the shares are acquired;	Rs 10/- per share (face value)
9	Percentage of shareholding / control acquired and / or number of shares acquired;	Pre-acquisition holding: NIL Post-acquisition holding (Proposed): 39,67,800 equity shares of Rs 10/- amounting of Rs. 3,96,78,000/- constituting 51% equity stake
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Date of incorporation: October 19, 2019 Product/line of business: Pharmaceuticals and Chemical Industry Last 3 years' turnover: Financial year 2021-22: 35,08,25,152.94/- Financial year 2022-23- 28,77,39,633.10/- Financial year 2023-24- Rs. 20,58,08,887/- Presence of entity: India